TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06205381
Drug: AV078
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral solution containing active ingredient, AV078
Study: NCT06205381
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily oral dose of 200 mg itraconazole administered for 9 days
Study: NCT06205381
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 mg midazolam administered orally on day 1 and day 18
Study: NCT06205381
Drug: Fexofenadine
Normalized name: Fexofenadine
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg fexofenadine administered orally on day 1 and day 18
Study: NCT05781321
Drug: Fluorodopa F 18
Normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05781321
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05459402
Drug: Methadone (100% dose)
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone for the treatment of opioid use disorder
Study: NCT05459402
Drug: Methadone (50% dose)
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methadone for the treatment of opioid use disorder
Study: NCT06056830
Drug: 64Cu-SAR-bisPSMA
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
Study: NCT06117306
Drug: 3,4 Methylenedioxymethamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 MDMA session
Study: NCT05248997
Drug: rimegepant 75 mg ODT
Normalized name: rimegepant
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One dose of rimegepant 75 mg ODT
Study: NCT04505501
Drug: N-803
Normalized name: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
DrugBank: Inbakicept (DB16479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-803 is a novel IL-15 superagonist complex that enhances NK cell and CD8+ T-cell proliferation and activation.
Study: NCT06330064
Drug: Ifinatamab deruxtecan
Normalized name: Ifinatamab deruxtecan
DrugBank: Ifinatamab deruxtecan (DB18212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05898412
Drug: Andexanet alfa
Normalized name: andexanet alfa
DrugBank: Andexanet alfa (DB14562)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients treated with andexanet alfa
Study: NCT06289673
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per mouth (PO) or intravenously (IV) once on Day 1 and PO or IV divided BID (every 12 hours) days 2-7
Study: NCT06289673
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously (IV) for 1 dose on Day 1 or 2
Study: NCT06289673
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenously (IV) for 1 dose on Day 2 or 3 (T-ALL/ T-LLy/ MPAL only)
Study: NCT06289673
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal (Age adjusted) for 1 dose on Day 4 or 5 or 6
Study: NCT06289673
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT as part of Intrathecal triple therapy.
Study: NCT05270434
Drug: morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
Study: NCT06326697
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 300 mg Film coated tablets
Study: NCT06326697
Drug: Onureg
Normalized name: Onureg
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 300 mg Film coated tablets
Study: NCT05018286
Drug: Apraglutide
Normalized name: Apraglutide
DrugBank: Apraglutide (DB18084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
Study: NCT05695898
Drug: XmAb23104
Normalized name: IMMUNOGLOBULIN, ANTI-(HUMAN PROGRAMMED CELL DEATH 1) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB23104 SINGLE-CHAIN VARIABLE FRAGMENT VL-LINKER-VH) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (260->234'),(263->237')-
DrugBank: Izuralimab (DB18933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously (IV)
Study: NCT05655507
Drug: Zuranolone
Normalized name: Zuranolone
DrugBank: Zuranolone (DB15490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as capsules
Study: NCT05457283
Drug: Finerenone (Kerendia, BAY94-8862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Finerenone in different doses, treatment duration will be 540 ±7 days.
Study: NCT06121349
Drug: ocrelizumab
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: infusion therapy administered every six months
Study: NCT06121349
Drug: ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: self-injectable every month
Study: NCT06107803
Drug: Roluperidone 64 mg
Normalized name: Domperidone
DrugBank: Roluperidone (DB13080)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg/day oral
Study: NCT06107803
Drug: Olanzapine 10 MG
Normalized name: olanzapine 10 MG
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/day oral
Study: NCT06356259
Drug: IRX-010
Normalized name: IRX-2
DrugBank: IRX-2 (DB05643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT06038578
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Study: NCT06038578
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Study: NCT04569461
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg of pembrolizumab (KEYTRUDA) will be given by IV every 6 weeks for 9 cycles, for approximately one year of study drug administration.
Study: NCT06445972
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/M\^2 IV infusion
Study: NCT05499832
Drug: Tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to IA treatment will receive IA TNK via a standard approved microcatheter positioned as close as possible to the residual occlusion site or as distal as possible in the originating vessel if multiple residual occlusions exists.
Study: NCT04724369
Drug: 18F-MFBG
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
Study: NCT06397703
Drug: Leuprolide, Degarelix or Relugolix
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to the androgen deprivation therapy (ADT) arm will be treated with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
Study: NCT05473156
Drug: AP203
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight dose levels ranging from 0.00064 to 20 mg/kg will be evaluated to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) or the recommended phase 2 dose(s) (RP2D\[s\]).~Participants will be administered by intravenous (IV) infusion, every week (Q1W \[± 1days\]) for the first 3 weeks (from the first to the fourth dose), then administered every 2 weeks (Q2W \[± 3 days\]) for all the following doses.
Study: NCT05473156
Drug: AP203
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dose-expansion phase will be conducted following completion of dose escalation for AP203. Participants will receive AP203 by IV infusion, administered Q1W (± 1 days) for the first 3 weeks (from the first to the fourth dose), then administered Q2W (± 3 days) for all the following doses, at the RP2D for each expansion cohort.
Study: NCT06078592
Drug: Combigan Eye drops
Normalized name: Combigan
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combigan Eye drops
Study: NCT06138743
Drug: ARO-DM1 for Injection
Normalized name: Trastuzumab-DM1
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single or multiple doses of ARO-DM1 by intravenous (IV) infusion
Study: NCT05705258
Drug: Aflibercept (Eylea, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with Intravitreal (IVT)-AFL must be made by the treating ophthalmologist
Study: NCT05596409
Drug: Elacestrant
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 400 mg elacestrant dihydrochloride administered orally once daily for an estimated 6 months of treatment.
Study: NCT06188520
Drug: Camizestrant
Normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SERD
Study: NCT06188520
Drug: Ribociclib
Normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CDK4/6 inhibitor
Study: NCT06188520
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor
Study: NCT06188520
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor
Study: NCT06400472
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV
Study: NCT06400472
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT06360354
Drug: AMG 193
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Orally
Study: NCT06360354
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT06360354
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT05170204
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive oral alectinib twice daily with food.
Study: NCT05170204
Drug: Entrectinib
Normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral entrectinib once daily, with or without food.
Study: NCT05170204
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV durvalumab every 4 weeks.
Study: NCT06433505
Drug: BMS-986365
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05039619
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1, Day 14, Week 24, Week 26 and Week 52.
Study: NCT05039619
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate Mofetil (MMF) will be taken by home administration orally at a target dose of 1200 mg/m\^2/day to a maximum of 2.5g/day from baseline (Day 1) onwards.
Study: NCT05039619
Drug: Diphenhydramine hydrochloride (HCl)
Normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine HCl 50 mg will be administered as pre-medication prior to infusions.
Study: NCT05039619
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 80 mg IV will be administered as pre-medication prior to infusions.
Study: NCT05039619
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone or equivalent corticosteroid will be taken by home administration daily to a maximum dose of 60mg/day followed by a guided taper to 5mg/day or less by Week 24.
Study: NCT06081179
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of psilocybin (15mg), orally in form of capsules
Study: NCT06081179
Drug: 3,4 Methylenedioxymethamphetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MDMA (100mg), orally in form of capsules
Study: NCT06081179
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of methylphenidate (60mg), orally in form of capsules
Study: NCT05047263
Drug: Finerenone (BAY94-8862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, 10 mg or 20 mg, once daily (OD), oral
Study: NCT06548139
Drug: Rabies Human Immunoglobulin (HRIG)
Normalized name: Rabies immunoglobulin (human)
DrugBank: Rabies immune globulin, human (DB11603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: Rabid human immunoglobulin
Study: NCT06500702
Drug: frexalimab
Normalized name: Frexalimab
DrugBank: Frexalimab (DB18926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: frexalimab treatment
Study: NCT06500702
Drug: rilzabrutinib
Normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilzabrutinib treatment
Study: NCT04649385
Drug: BGB-15025
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once or twice daily (QD or BID)
Study: NCT04649385
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 200 mg intravenous (IV) infusion
Study: NCT06119789
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: imatinib treatment based on molecular alterations
Study: NCT06119789
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: According to biomarkers
Study: NCT06119789
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: According to biomarkers
Study: NCT05629208
Drug: Edecesertib
Normalized name: Edecesertib
DrugBank: Edecesertib (DB18917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05629208
Drug: Edecesertib Placebo
DrugBank: Edecesertib (DB18917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT06253195
Drug: BGB-43395
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06253195
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered via intramuscular injection.
Study: NCT06253195
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05083208
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ib: Parsaclisib is taken orally every day continuously, at approximately the same time every day, without food restriction, once a day. This stage follows the traditional 3+3 model. Parsaclisib is set at 10 mg/day, 15 mg/day, 20 mg/day 3 dose groups, starting from 10 mg/day, each group included 3 subjects. The final dose determined at this stage will be used in the Phase II study.~Phase II: Induced treatment: Received the initial dose of Parsaclisib determined in Phase Ib within the first 8 weeks (including the treatment received in Phase Ib).~Maintain treatment: 2.5mg orally every day continuously, at approximately the same time every day, without food restriction, once a day until disease progression, death or unacceptable toxicity developments. The maximum treatment time of Parsaclisib is no more than 2 years.
Study: NCT05083208
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Phase Ib: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast.~Phase II: Chidamide is taken fixed 20mg twice a week with an interval of no less than 3 days, and taken 30 minutes after breakfast until disease progression, death or unacceptable toxicity developments.
Study: NCT05911321
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Solution for infusion. Route of administration: Intravenous 10 mg/kg will be administered intravenously once weekly during cycle 1 and every other week during each subsequent cycle.
Study: NCT05911321
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Pill for oral use. Route of administration: 3 mg Pomalidomide 3 mg pill will be taken by mouth once daily on days 1-21 of each 28-day cycle.
Study: NCT05911321
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Tablet for oral use Route of administration: Pill for oral use. Dexamethasone 20 mg tablet will be taken by mouth once per week.
Study: NCT06600711
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mL suspension (100 mg), 2x/day for 3 days
Study: NCT06666855
Drug: DE-117B Eye Drops
Normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational Product: 0.002% DE-117B Eye Drops
Study: NCT06658002
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
Study: NCT06662539
Drug: Petrelintide
Normalized name: Petrelintide
DrugBank: Petrelintide (DB19442)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petrelintide will be taken by participants once weekly as a self-administered subcutaneous injection.
Study: NCT06661122
Drug: Darolutamide (BAY1841788) + docetaxel + ADT
Normalized name: darolutamide
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Follow clinical practice/administration. ADT=androgen deprivation therapy.
Study: NCT06592768
Drug: Briquilimab
Normalized name: Briquilimab
DrugBank: Briquilimab (DB18136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Administration
Study: NCT06586515
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously.
Study: NCT06586515
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT06586515
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously.
Study: NCT06586515
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT06586515
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT06586515
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT06666855
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active Control: 0.005% Latanoprost Eye Drops
Study: NCT04522102
Drug: Start antiplatelet monotherapy
Normalized name: Star Anise Oil
DrugBank: Anise oil (DB15776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start one antiplatelet drug, be available in local standard clinical practice, chosen by patient's physician pre-randomisation
Study: NCT06773130
Drug: HRS-4642
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-4642 will be administrated per dose level in which the patients are assigned.
Study: NCT06773130
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg，ivgtt，d1，qw
Study: NCT06691113
Drug: Itepekimab (SAR440340)
Normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous
Study: NCT06691113
Drug: Mometasone furoate nasal spray (MFNS)
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray
Study: NCT06727136
Drug: TBP-PI-HBr
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TBP-PI-HBr film-coated immediate-release tablets